





¹ Division of Infectious Diseases, Emory University School of Medicine ² Georgia Emerging Infections Program, ³ Atlanta Veterans Affairs Medical Center, ⁴Foundation for Atlanta Veterans Education and Research

Introduction

Carbapenem resistant Enterobacterales (CRE) infections are an urgent public health threat

Objectives: Identify risk factors for mortality in patients with invasive CRE infections and assess the association between indwelling devices and mortality

Methods

Population: Using the Georgia Emerging Infections Program's active, population-based surveillance of CRE in the Atlanta metropolitan area, we created a cohort of patients with invasive CRE infections between 2012-2019

Definition of Carbapenem-resistant Enterobacterales

| Organisms | Antibiotic Susceptibility Based on Minimum Inhibitory Concentration (MIC) | | |
|-----------------------|--|------------------------------|--|
| | Resistant to: | AND Resistant to: | |
| Escherichia coli | Imipenem (MIC >/= 4) or | Ceftazidime (MIC >/= 16) and | |
| Klebsiella pneumoniae | Meropenem (MIC >/= 4) or | Ceftriaxone (MIC >/=4) and | |
| Klebsiella oxytoca | Doripenem (MIC >/= 4) | Cefotaxime (MIC >/=4) | |
| Klebsiella aerogens | | (if tested) | |
| Enterobacter cloacae | | | |


Exposure of Interest: Indwelling medical devices *Outcome:* **90-day mortality** (via Georgia Vital Statistics)

Analyses:


- Bivariate analyses for all covariates
- Multivariable log binomial regression to estimate adjusted risk ratios for selected covariates and indwelling devices
- Subgroup analyses:
 - (1) Central venous catheters
 - (2) \geq two devices

LSW was supported in part by the NCATS of the NIH under awards UL1TR002378 and TL1TR002382. Additional funding from the Centers for Disease Control and Prevention U50CK000485, Emerging Infection Program

Evaluating Indwelling Devices and Mortality in Invasive Carbapenem-Resistant Enterobacterales Infections, Atlanta, GA, 2012–2019 Witt LS^{1,2}, Smith G^{2,3,4}, Sexton ME¹, Farley MM^{1,2}, Jacob JT^{1,2}









| icy | | | | | | |
|----------------------------|-------------------------------------|------------------------------|-------------------|-------------------|--|--|
| | Unadjusted | Adjusted 1 | Adjusted 2 | Adjusted 3 | | |
| | RR (95% CI) | RR (95% CI) | RR (95% CI) | RR (95% CI) | | |
| nt | 1.55 (0.53, 4.56) | 1.02 (0.36, 2.89) | | | | |
| r Present | 1.71 (0.81, 3.61) | | 1.13 (0.54, 2.37) | | | |
| | 2.81 (1.16, 6.77) | | | 2.48 (1.02, 5.99) | | |
| dex Score | 1.09 (0.98, 1.22) | 1.11 (0.38, 3.32) | 1.10 (0.98, 1.24) | 1.09 (0.97, 1.23) | | |
| ission | 3.54 (1.65, 7.59) | 3.24 (1.51, 6.95) | 3.17 (1.46, 6.85) | | | |
| 1 year) | 1.58 (0.88, 2.84) | 1.49 (0.51, 4.35) | 1.43 (0.81, 2.54) | 1.31 (0.75, 2.30) | | |
| rlson comorbidity score, I | ntensive care admission, previous s | stay at long term acute care | | - | | |
| | | | | | | |